InflaRx N.V (F:IF0) — Market Cap & Net Worth
Market Cap & Net Worth: InflaRx N.V (IF0)
InflaRx N.V (F:IF0) has a market capitalization of $50.33 Million (€43.05 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #21848 globally and #1941 in its home market, demonstrating a 43.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InflaRx N.V's stock price €1.83 by its total outstanding shares 67747130 (67.75 Million). Analyse InflaRx N.V cash flow conversion to see how efficiently the company converts income to cash.
InflaRx N.V Market Cap History: 2017 to 2026
InflaRx N.V's market capitalization history from 2017 to 2026. Data shows change from $1.35 Billion to $144.94 Million (-20.49% CAGR).
InflaRx N.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InflaRx N.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1244.03x
InflaRx N.V's market cap is 1244.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $121.02 Million | $63.09K | -$42.67 Million | 1918.29x | N/A |
| 2024 | $206.25 Million | $165.79K | -$46.06 Million | 1244.03x | N/A |
Competitor Companies of IF0 by Market Capitalization
Companies near InflaRx N.V in the global market cap rankings as of May 5, 2026.
Key companies related to InflaRx N.V by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
InflaRx N.V Historical Marketcap From 2017 to 2026
Between 2017 and today, InflaRx N.V's market cap moved from $1.35 Billion to $ 144.94 Million, with a yearly change of -20.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €144.94 Million | +105.62% |
| 2025 | €70.49 Million | -65.82% |
| 2024 | €206.25 Million | +70.42% |
| 2023 | €121.02 Million | -42.60% |
| 2022 | €210.84 Million | -30.86% |
| 2021 | €304.93 Million | -10.47% |
| 2020 | €340.58 Million | +12.57% |
| 2019 | €302.56 Million | -84.96% |
| 2018 | €2.01 Billion | +48.96% |
| 2017 | €1.35 Billion | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of InflaRx N.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.33 Million USD |
| MoneyControl | $50.33 Million USD |
| MarketWatch | $50.33 Million USD |
| marketcap.company | $50.33 Million USD |
| Reuters | $50.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal … Read more